Clinical Research Solutions
FDA Issues Draft Guidance for Industry, Considerations for Rescinding Breakthrough Therapy Designation
Draft Guidance June 24, 2022 The U.S. Food and Drug Administration issued a draft guidance for industry titled Considerations for Rescinding Breakthrough Therapy Designation. This draft guidance...